Paclitaxel (TAXOL®) concentrations in brain tumor tissue
| Autor: | O. W. M. Meijer, Jan B. Vermorken, Martin J B Taphoorn, J. J. Heimans, C. Eeltink, Jos H. Beijnen, J. G. Wolbers |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male Pathology medicine.medical_specialty Paclitaxel medicine.medical_treatment Brain tumor Pilot Projects Blood–brain barrier chemistry.chemical_compound Cerebrospinal fluid Glioma medicine Humans Tissue Distribution Cyst Chemotherapy Brain Neoplasms business.industry Brain Hematology medicine.disease medicine.anatomical_structure Oncology chemistry Blood-Brain Barrier business Perfusion |
| Zdroj: | Annals of Oncology. 5:951-953 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/oxfordjournals.annonc.a058736 |
| Popis: | Summary Background Paclitaxel (Taxol®) is a novel chemotherapeutic agent, active against a variety of tumors. It is not known whether the drug penetrates brain tumor tissue. Patients and methods Three patients with a recurrent glioma received paclitaxel (175 mg/m2) in a 3-hour i.v. infusion prior to surgery. Paclitaxel concentrations were measured in the tumor tissue, cerebrospinal fluid, cyst fluid, plasma and, in one patient, normal brain tissue. Results Tumor tissue concentrations were in the thera- peutic range in all three patients. Brain tissue concentration, however, was below the detection limit of the trial. Conclusions These findings suggest that paclitaxel may have a place in brain tumor therapy. The low concentration in normal brain tissue, as observed in one patient, may suggest, however, that the drug does not cross the intact blood-brain barrier. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|